42508-60-1

Usage

Chemical Properties

Light brown powder

Uses

N-Acetonylpyridinium chloride is used as a pharmaceutical intermediate.

InChI:InChI=1/C8H10NO.ClH/c1-8(10)7-9-5-3-2-4-6-9;/h2-6H,7H2,1H3;1H/q+1;/p-1

Upstream product

• 110-86-1 pyridine 
• 78-95-5 chloroacetone 

Downstream Products

• 129169-85-3 C₁₄H₁₇NO₃S₂ 
• 37026-10-1 Cyano-acetyl-pyridinium-methylid 
• 623-51-8 ethyl 2-sulfanylacetate 
• 195967-12-5 4'-ethoxy-6,6''-dimethyl-4,4''-di(p-tolyl)-2,2':6',2''-terpyridine 
• 110-86-1 pyridine 
• 862651-16-9 5-(adamantyl-1-yl)-4'-bromobiphenyl-3-ol 
• 1209004-01-2 5-(p-bromobenzoyl)-4-methyl-3-(1-pyridino)thiophene-2-thiolate 
• 1209003-99-5 5-benzoyl-4-methyl-3-(1-pyridino)thiophene-2-thiolate 
• 1209004-00-1 5-(p-chlorobenzoyl)-4-methyl-3-(1-pyridino)thiophene-2-thiolate 
• 144342-48-3 4,4'-Bis(fur-2-yl)-6,6'-dimethyl-2,2'-bipyridine 
• 120221-69-4 3-acetylindolizin-1-yl-carboxylic acid 

Relevant academic research and scientific papers

New indolizine–chalcones as potent inhibitors of human farnesyltransferase: Design, synthesis and biological evaluation

A new family of indolizine–chalcones was designed, synthesized and screened for the inhibitory potential on human farnesyltransferase in vitro to identify potent antitumor agents. The most active compound was phenothiazine 2a, exhibiting an IC50/sub

An efficient one-pot method for a highly stereoselective base-catalysed synthesis of novel trans-spirocyclopropane-indanedione derivatives

A one-pot, efficient, synthesis of six novel trans-spirocyclopropane-indanedione derivatives with high stereoselectivity has been achieved via the reaction of acetopyridinium chloride with 1,3-indandione and an araldehyde in the presence of triethylamine in acetonitrile under reflux conditions. The attractive features of the method are excellent yields and high purity, short reaction times, and easy work-up.

Indolizine-phenothiazine hybrids as the first dual inhibitors of tubulin polymerization and farnesyltransferase with synergistic antitumor activity

In the incessant search for innovative cancer control strategies, this study was devoted to the design, synthesis and pharmacological evaluation of dual inhibitors of farnesyltransferase and tubulin polymerization (FTI/MTIs). A series of indolizine-phenothiazine hybrids 16 (amides) and 17 (ketones) has been obtained in a 4-step procedure. The combination of the two heterocycles provided potent tubulin polymerization inhibitors with similar efficiency as the reference phenstatin and (-)-desoxypodophyllotoxin. Ketones 17 were also able to inhibit human farnesyltransferase (FTase) in vitro. Interestingly, three molecules 17c, 17d and 17f were very effective against both considered biological targets. Next, nine indolizine-phenothiazine hybrids 16c, 16f, 17a-f and 22b were evaluated for their cell growth inhibition potential on the NCI-60 cancer cell lines panel. Ketones 17a-f were the most active and displayed promising cellular activities. Not only they arrested the cell growth of almost all tested cancer cells, but they displayed cytotoxicity potential with GI50 values in the low nanomolar range. The most sensitive cell lines upon treatment with indolizine-phenothiazine hybrids were NCI-H522 (lung cancer), COLO-205 and HT29 (colon cancer), SF-539 (human glioblastoma), OVCAR-3 (ovarian cancer), A498 (renal cancer) and especially MDA-MB-435 (melanoma). Demonstrating the preclinical effectiveness of these dual inhibitors can be crucial. A single dual molecule could induce a synergy of antitumor activity, while increasing the effectiveness and reducing the toxicity of the classical combo treatments currently used in chemotherapy.

Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B

Bromodomains are acetyl-lysine specific protein interaction domains that have recently emerged as a new target class for the development of inhibitors that modulate gene transcription. The two closely related bromodomain containing proteins BAZ2A and BAZ2B constitute the central scaffolding protein of the nucleolar remodeling complex (NoRC) that regulates the expression of noncoding RNAs. However, BAZ2 bromodomains have low predicted druggability and so far no selective inhibitors have been published. Here we report the development of GSK2801, a potent, selective and cell active acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains as well as the inactive control compound GSK8573. GSK2801 binds to BAZ2 bromodomains with dissociation constants (KD) of 136 and 257 nM for BAZ2B and BAZ2A, respectively. Crystal structures demonstrated a canonical acetyl-lysine competitive binding mode. Cellular activity was demonstrated using fluorescent recovery after photobleaching (FRAP) monitoring displacement of GFP-BAZ2A from acetylated chromatin. A pharmacokinetic study in mice showed that GSK2801 had reasonable in vivo exposure after oral dosing, with modest clearance and reasonable plasma stability. Thus, GSK2801 represents a versatile tool compound for cellular and in vivo studies to understand the role of BAZ2 bromodomains in chromatin biology.

Design, Synthesis, and Biological Evaluation of 6-Substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: A Novel Class of Diarylheterocyclic Selective Cyclooxygenase-2 Inhibitors

A group of 6-alkyl (alkoxy or alkylthio)-4-aryl-3-(4-methanesulfonylphenyl)pyran-2-ones (14a-v), possessing either a H or F substituent at the para-position of the C-4 phenyl ring, were designed for evaluation as selective cyclooxygenase-2 (COX-2) inhibit

Process for the preparation of phenylphenol compounds

There is described the preparation of phenylphenol compounds of formula (I) by reaction of a keto compound of formula (3) with dioxolane of formula (4) and with an ammonium compound of formula (5) to form a β-aminoketone compound of formula (6) (reaction step (I)), reaction of the compound of formula (6) with a compound of formula (7) to form a compound of formula (2) (reaction step (II)), and subsequent alkylation to form a compound of formula (I) (reaction step (III)) in accordance with scheme (A); wherein R1, R2, R3, R6 and R7 are each independently of the others hydrogen or C1-C8-alkyl; R4, R5 and R8 are each independently of the others hydrogen or C1-C5alkyl; and Hal is a halogen atom. The compounds prepared in accordance with the invention are suitable as antimicrobial active substances.